trending Market Intelligence /marketintelligence/en/news-insights/trending/pyOiahJ4vQa75oZRYntTKg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Vertex Pharmaceuticals inks deal with NHS for access to 3 cystic fibrosis drugs

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Vertex Pharmaceuticals inks deal with NHS for access to 3 cystic fibrosis drugs

Vertex Pharmaceuticals Inc. said its cystic fibrosis medicines Orkambi, Symkevi and Kalydeco will be available on the National Health Service in England following an access agreement between the company and NHS.

Cystic fibrosis is a life-threatening and rare inherited disease which causes the buildup of sticky mucus in the lungs and digestive system, potentially leading to severe damage of the affected organs. The disorder is due to alterations in the CFTR gene, with F508del mutation being the most common gene defect.

Under the agreement, patients will have full access to the three therapies for free through the NHS, with no limit on patient numbers. The deal covers all current and future license indications of Orkambi, Symkevi and Kalydeco.

Orkambi, or lumacaftor/ivacaftor, is approved to treat cystic fibrosis in patients aged two years and older whose disease has the F508del mutation in the CFTR gene. Additionally, Symkevi, a combination of tezacaftor/ivacaftor, is for the same indication in patients who are 12 years old and above.

Kalydeco, also known as ivacaftor, is indicated for patients aged one year and older and whose cystic fibrosis is positive for one of nine mutations. Boston-based Vertex said Kalydeco is the first approved treatment targeting the underlying cause of cystic fibrosis in people with specific mutations in the CFTR gene.

The National institute for Health and Care Excellence has backed the agreement. As part of the transaction, NICE will conduct a full appraisal of the Vertex drugs, along with the company's new triple therapy.

Commercial terms of the agreement are confidential.